We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+19.02%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$2.7B
AUM Growth
-$133M
Cap. Flow
-$358M
Cap. Flow %
-13.27%
Top 10 Hldgs %
54.24%
Holding
107
New
20
Increased
12
Reduced
35
Closed
22

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$157M
2
OMDA
Omada Health Inc
OMDA
+$42M
3
ROIV icon
Roivant Sciences
ROIV
+$36.1M
4
CAI
Caris Life Sciences
CAI
+$29.6M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$17.8M

Top Sells

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$104M
2
FOLD
Amicus Therapeutics
FOLD
+$90.7M
3
SLNO
Soleno Therapeutics
SLNO
+$80.5M
4
VRNA
Verona Pharma
VRNA
+$78.2M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$42.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRNA
1
DELISTED
Verona Pharma
VRNA
$521M 19.31%
5,507,591
-1,055,749
-16% -$78.2M
ASND icon
2
Ascendis Pharma A/S
ASND
$17.1B
$166M 6.17%
+963,886
New +$157M
ACLX
3
DELISTED
Arcellx
ACLX
$163M 6.05%
2,478,000
-448,478
-15% -$27.9M
RYTM icon
4
Rhythm Pharmaceuticals
RYTM
$7.31B
$153M 5.67%
2,418,299
-130,146
-5% -$7.97M
NUVL
5
DELISTED
Nuvalent
NUVL
$105M 3.89%
1,375,180
-258,788
-16% -$18.9M
AORT icon
6
Artivion
AORT
$1.22B
$86.9M 3.22%
2,793,703
– –
MGTX icon
7
MeiraGTx Holdings
MGTX
$1.15B
$82.2M 3.05%
12,626,103
+45,000
+0.4% +$266K
INSM icon
8
Insmed
INSM
$23.5B
$65.4M 2.43%
650,252
+140,952
+28% +$10.8M
EWTX icon
9
Edgewise Therapeutics
EWTX
$4.28B
$60.8M 2.26%
4,639,949
-1,907,379
-29% -$27.5M
PTGX icon
10
Protagonist Therapeutics
PTGX
$9.06B
$59.4M 2.2%
1,074,448
-16,823
-2% -$807K
SLDB icon
11
Solid Biosciences
SLDB
$858M
$58M 2.15%
11,906,646
– –
APGE icon
12
Apogee Therapeutics
APGE
$10.1B
$51.3M 1.9%
1,182,148
+59,381
+5% +$2.26M
AMLX icon
13
Amylyx Pharmaceuticals
AMLX
$1.97B
$50.7M 1.88%
7,902,365
+28,017
+0.4% +$136K
IMTX icon
14
Immatics
IMTX
$1.31B
$50.5M 1.87%
9,383,456
– –
AKRO
15
DELISTED
Akero Therapeutics
AKRO
$48.9M 1.81%
915,887
+122,927
+16% +$5.59M
OMDA
16
Omada Health Inc
OMDA
$1.41B
$44.4M 1.65%
+2,426,330
New +$42M
FOLD
17
DELISTED
Amicus Therapeutics
FOLD
$42.5M 1.57%
7,412,830
-14,051,697
-65% -$90.7M
ROIV icon
18
Roivant Sciences
ROIV
$24.8B
$37.5M 1.39%
+3,331,465
New +$36.1M
MRUS
19
DELISTED
Merus
MRUS
$37.3M 1.38%
708,176
+17,691
+3% +$832K
SLNO
20
DELISTED
Soleno Therapeutics
SLNO
$36.1M 1.34%
430,439
-1,076,163
-71% -$80.5M
ATXS
21
DELISTED
Astria Therapeutics
ATXS
$34.8M 1.29%
6,485,420
– –
IMVT icon
22
Immunovant
IMVT
$8.27B
$34.2M 1.27%
2,137,890
-706,182
-25% -$10.7M
NBIX icon
23
Neurocrine Biosciences
NBIX
$17.2B
$32.1M 1.19%
255,050
+155,000
+155% +$17.8M
PRAX icon
24
Praxis Precision Medicines
PRAX
$8.77B
$31.7M 1.17%
752,921
-227,973
-23% -$8.68M
BSX icon
25
Boston Scientific
BSX
$65.4B
$30.1M 1.12%
280,000
+150,000
+115% +$15.2M
1
2 3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q2 2025 Portfolio in Review

As of Q2 2025, Perceptive Advisors held 107 positions worth $2.7B, down 4.7% from $2.83B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Perceptive Advisors withdrew a net $358M in Q2 2025, closing 22 positions and reducing 35 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $104M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

Against the trend, Perceptive Advisors opened a new position in Ascendis Pharma A/S worth $166M.

  • Perceptive Advisors's largest Q2 2025 buy was Ascendis Pharma A/S: 963,886 shares worth $166M.
  • Perceptive Advisors added most to Neurocrine Biosciences in Q2 2025, an estimated $17.8M increase.
  • Perceptive Advisors's biggest Q2 2025 reduction was Amicus Therapeutics, cutting an estimated $90.7M.
  • Perceptive Advisors fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $104M.
  • Perceptive Advisors's ten largest holdings make up 54% of its $2.7B portfolio in Q2 2025.
  • Perceptive Advisors opened 20 new positions and closed 22 in Q2 2025.
  • Perceptive Advisors's portfolio value fell 4.7% quarter-over-quarter to $2.7B.

Based on Perceptive Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.